{"filing":{"accession_number":"0001437749-26-025506","cik":"0001710340","ticker":"ETON","company_name":"Eton Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-07-31","primary_document":"eton20260731_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926025506/eton20260731_8k.htm"},"events":[{"id":23955,"run_id":21667,"accession_number":"0001437749-26-025506","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Danka Radosavljevic was appointed Chief Operating Officer on July 31, 2026, a material executive position. While the disclosure also includes compensation details (base salary of $520,800 and 50% bonus target), the principal disclosed action is the appointment to the COO role. The appointment of a C-suite officer is material to investors assessing company leadership and governance.","company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24320,"accession_number":"0001437749-26-025506","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Danka Radosavljevic was appointed Chief Operating Officer on July 31, 2026, a material executive position. While the disclosure also includes compensation details (base salary of $520,800 and 50% bonus target), the principal disclosed action is the appointment to the COO role. The appointment of a C-suite officer is material to investors assessing company leadership and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:33:44.142452+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24320,"accession_number":"0001437749-26-025506","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Danka Radosavljevic was appointed Chief Operating Officer on July 31, 2026, a material executive position. While the disclosure also includes compensation details (base salary of $520,800 and 50% bonus target), the principal disclosed action is the appointment to the COO role. The appointment of a C-suite officer is material to investors assessing company leadership and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:33:44.142452+00:00","company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","filing_date":"2026-08-04"}]}